Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years (stratum 2),...

詳細記述

保存先:
書誌詳細
出版年:Blood
主要な著者: Brandão, Leonardo R., Albisetti, Manuela, Halton, Jacqueline, Bomgaars, Lisa, Chalmers, Elizabeth, Mitchell, Lesley G., Nurmeev, Ildar, Svirin, Pavel, Kuhn, Tomas, Zapletal, Ondrej, Tartakovsky, Igor, Simetzberger, Monika, Huang, Fenglei, Sun, Zhichao, Kreuzer, Jörg, Gropper, Savion, Brueckmann, Martina, Luciani, Matteo
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2020
主題:
Clinical Trials and Observations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019192/
https://ncbi.nlm.nih.gov/pubmed/31805182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000998
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料